Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - November 2013


Cell Based Assays

18 Nov 2013 - 19 Nov 2013 - London, UK



Bookmark and Share


SMi is proud to present their 6th Annual...

Cell Based Assays

Following on from our hugely successful Cell-Based Assays conference in 2012, this year's agenda will provide a global forum for senior level decision makers and those working within Cell-Based Assays to meet.

Highly accurate in-vitro practices are becoming absolutely vital as is looking at cost-effective assay development. Cell based assays now play an important role into the research pipeline, making a large percentage of total research time and is set to show considerable growth over the coming years.

There are currently 15 FDA approved kinase inhibitor drugs, but there currently remains a huge uncapped potential with these drugs as over 90% of the kinome is unknown. Novel assays have identified kinase targets, improved the function of kinase inhibitors and led to an acceleration in drug discovery with new inhibitor classes.

See at Cell Based Assays 2013 how HCA can be utilised in your pre-clinical toxicology procedures to give highly accurate data.

WHY ATTEND THIS EVENT: 

Hear the latest on Phenotypic screening; how target based screening is allowing for identification of small molecules

See how you can implement a primary cell assay plan through a case study of SARdriving assay

The latest in GPCR and other ion channel targeting pathways and how they are being used in the most recent drug discovery assays

Adopt accelerated primary cell screening systems such as those utilised by GSK

KEYNOTE SPEAKERS INCLUDE:

Mao Xiang Chen, Biological and Cellular targets, GlaxoSmithKline

Martha Brown, Senior Associate Director, Boehringer-Ingelheim

Xavier Leroy, Director, Actelion

Steve Ludbrook, Section Head, GlaxoSmithKline

Urs Luethi, Senior Lab Head Discovery, Actelion

Anthony Davies, Director, Trinity College Dublin

Tyrell Norris, Team Leader – Cellular Reagents & Assay Development, AstraZeneca

Amir Gander, Senior Knowledge Transfer Associate, University College London

**Book by 19th July 2013 and save £300**

**Book by 31st September 2013 and save £100**

Visit our website here:  http://ww.smi-online.co.uk/goto/2013cellbasedassay20.asp

Alternatively, contact Fateja Begum on +44 (0)20 7827 6184 or email:  fbegum@smi-online.co.uk



Further information
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!